Oncolytics Biotech (TSE:ONC) PT Raised to C$3.50 at Raymond James

Oncolytics Biotech (TSE:ONC) had its price target increased by Raymond James from C$3.00 to C$3.50 in a research report sent to investors on Friday, BayStreet.CA reports.

Oncolytics Biotech Price Performance

Shares of ONC opened at C$1.23 on Friday. Oncolytics Biotech has a twelve month low of C$1.20 and a twelve month high of C$3.10. The company has a 50 day moving average of C$1.34 and a two-hundred day moving average of C$1.42. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09. The company has a market cap of C$94.54 million, a price-to-earnings ratio of -3.24 and a beta of 1.38.

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings data on Thursday, August 1st. The company reported C($0.10) EPS for the quarter, hitting the consensus estimate of C($0.10). As a group, analysts predict that Oncolytics Biotech will post -0.41 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.